Encoded Therapeutics Provides Pipeline Updates From Its Vector Engineering Platform Ahead of Four Preclinical Presentations at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Encoded Therapeutics Inc., a biotechnology company developing genetic medicines for severe central nervous system (CNS) disorders, today unveiled multiple pipeline programs ahead of the 27th ASGCT Annual meeting on May 7 - 11, 2024 in Baltimore, MD. Presentations will highlight progress of preclinical programs for Angelman syndrome, Lennox-Gastaut syndrome (LGS), STXBP1-related disorders (STXBP1-RD), Alzheimer’s disease (MAPT) and neuropathic pain (